Cellectis Presents Preclinical .HEAL-101 Data At ESGCT 2026 Showing Up To 70% In Vivo Human APOC3 Editing, 75% Triglyceride Reduction In Mouse Model; Plans Phase 1 China Trial

Loading news article.

Cellectis Presents Preclinical .HEAL-101 Data At ESGCT 2026 Showing Up To 70% In Vivo Human APOC3 Editing, 75% Triglyceride Reduction In Mouse Model; Plans Phase 1 China Trial | WAPE

Cellectis Presents Preclinical .HEAL-101 Data At ESGCT 2026 Showing Up To 70% In Vivo Human APOC3 Editing, 75% Triglyceride Reduction In Mouse Model; Plans Phase 1 China Trial

Article summary

Related companies

Analyzed by WAPE AI.

Comments —